|
시장보고서
상품코드
1888637
혈전증 치료제 시장 규모, 점유율, 동향 분석 : 질환 종류별, 약물 종류별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)Thrombosis Drugs Market Size, Share & Trends Analysis Report By Disease Type (Deep Vein Thrombosis, Pulmonary Embolism), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033 |
||||||
혈전증 치료제 : 시장 개요
세계의 혈전증 치료제 시장 규모는 2024년에 261억 1,000만 달러로 추정되며, 2033년까지 523억 달러에 달할 것으로 예측됩니다.
2025년부터 2033년까지 8.03%의 CAGR을 기록할 것으로 예상됩니다. 이 시장의 성장은 주로 전 세계 심혈관질환(CVD)의 높은 유병률에 의해 주도되고 있습니다. 심장마비, 뇌졸중, 정맥혈전색전증(VTE) 등의 질환이 증가함에 따라 효과적인 항응고요법에 대한 수요가 증가하고 있습니다.
세계 인구의 고령화도 시장 성장에 기여하고 있습니다. 노인은 혈전증 및 관련 합병증 위험이 높기 때문입니다. 보다 안전하고 편리한 경구용 약물을 포함한 항응고 요법의 발전은 환자의 치료 결과를 개선하고 보급을 촉진하는 데 기여하고 있습니다. 또한 비만, 당뇨병, 고혈압 등 생활습관병의 증가 추세, 혈전증 위험에 대한 인식 증가, 의료비 지출 증가가 맞물리면서 시장의 지속적인 성장을 뒷받침하고 있습니다.
제품 혁신과 규제 당국의 승인은 치료 옵션의 확대와 임상의의 신뢰도 향상을 통해 혈전증 치료제 산업을 주도하고 있습니다. 신속하고 간편한 혈전용해제, 개량형 경구용 항응고제 등 최근 의약품 및 의료기기의 발전은 치료 효과를 높이고 공급을 간소화하여 임상 현장에서의 채택을 촉진하고 시장 성장을 뒷받침하고 있습니다. 예를 들어, 2025년 3월에는 유전자 치료제 'TNKase'가 미국 식품의약국(FDA)으로부터 급성 허혈성 뇌졸중(AIS) 치료제로 승인받았습니다. 이 제품은 5초간 1회 정맥 내(IV) 볼러스로 투여되며, 표준 Activase(정맥내 볼러스를 투여한 후 60분 동안 지속 주입해야 함)보다 빠르고 간편한 대안이 될 수 있습니다.
국제혈전지혈학회(ISTH)가 주최하는 '세계 혈전증의 날' 등 전 세계 혈전증 예방 및 조기발견의 중요성을 강조하며 혈전증 치료제 시장을 간접적으로 지지하고 있습니다.
자주 묻는 질문
목차
제1장 분석 방법·범위
제2장 주요 요약
제3장 혈전증 치료제 시장 : 변수, 동향, 범위
- 시장 연관 전망
- 시장 역학
- 사업 환경 분석
- 업계 분석 : Porter's Five Forces 분석
- PESTLE 분석
- 파이프라인 분석
제4장 혈전증 치료제 시장 : 질환 종류별 사업 분석
- 시장 점유율 : 질환 종류별(2024년·2033년)
- 시장 규모 예측과 동향 분석 : 질환 종류별(2021-2033년)
- 심부정맥혈전증
- 폐색전증
- 심방세동
제5장 혈전증 치료제 시장 : 약물 종류별 사업 분석
- 시장 점유율 : 약물 종류별(2024년·2033년)
- 시장 규모 예측과 동향 분석 : 약물 종류별(2021-2033년)
- 제Xa인자 억제제
- 트롬빈 억제제
- 헤파린
- P2Y12 혈소판 수용체 억제제
- 기타
제6장 혈전증 치료제 시장 : 유통 채널별 사업 분석
- 시장 점유율 : 유통 채널별(2024년·2033년)
- 시장 규모 예측과 동향 분석 : 유통 채널별(2021-2033년)
- 병원 약국
- 소매 약국
- 온라인 약국
제7장 혈전증 치료제 시장 : 지역별 추정·동향 분석
- 시장 점유율 분석 : 지역별(2024년·2033년)
- 시장 대시보드 : 지역별
- 시장 규모 예측과 동향 분석(2021-2033년)
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제8장 경쟁 구도
- 진출 기업 외용
- 기업의 시장 포지션 분석
- 기업 분류
- 전략 매핑
- 기업 개요/리스트
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Boehringer Ingelheim International GmbH
- SANOFI
- AstraZeneca
- Pfizer Inc.
- CSL
- Novo Nordisk A/S
- Takeda Pharmaceutical Company Limited
- Ionis Pharmaceuticals
- Grifols, S.A.
- Aspen Holdings
Thrombosis Drugs Market Summary
The global thrombosis drugs market size was estimated at USD 26.11 billion in 2024 and is projected to reach USD 52.30 billion by 2033, growing at a CAGR of 8.03% from 2025 to 2033. The growth of this market is primarily driven by the high prevalence of cardiovascular diseases (CVDs) worldwide, as conditions such as heart attack, stroke, and venous thromboembolism (VTE) increase the demand for effective anticoagulant therapies.
An aging global population further contributes to market growth, since older adults are more susceptible to thrombosis and related complications. Advances in anticoagulant therapies, including safer and more convenient oral options, improve patient outcomes and encourage wider adoption. In addition, the rising prevalence of lifestyle-related diseases such as obesity, diabetes, and hypertension, combined with growing awareness of thrombosis risks and increased healthcare expenditure, continues to support sustained market expansion.
Product innovation and regulatory approvals drive the thrombosis drugs industry by expanding treatment options and raising clinician confidence. Recent drug and device advances, including faster, easier-to-administer clot-dissolving medicines and improved oral anticoagulants, make treatment more effective and simpler to deliver, which supports market growth by increasing clinical uptake. For instance, in March 2025, Genetech's TNKase, a clot-dissolving agent, received the U.S. Food and Drug Administration (FDA) approval for treating acute ischemic stroke (AIS). It is delivered as a single five-second intravenous (IV) bolus, providing a quicker and simpler option than the standard Activase, which requires an IV bolus followed by a 60-minute infusion.
Global awareness initiatives, such as World Thrombosis Day, organized by the International Society on Thrombosis and Hemostasis (ISTH), help to highlight the importance of thrombosis prevention and early detection, thereby indirectly supporting the thrombosis drugs market.
Global Thrombosis Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global thrombosis drugs market report based on disease type, drug class, distribution channel, and region:
- Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- Factor Xa Inhibitors
- Thrombin Inhibitors
- Heparins
- P2Y12 Platelet Inhibitors
- Others
- Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Disease Type
- 1.2.2. Drug Class
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Thrombosis Drugs Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Thrombosis Drugs Market: Disease Type Business Analysis
- 4.1. Disease Type Market Share, 2024 & 2033
- 4.2. Disease Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
- 4.4. Deep Vein Thrombosis
- 4.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.5. Pulmonary Embolism
- 4.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 4.6. Atrial Fibrillation
- 4.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Thrombosis Drugs Market: Drug Class Business Analysis
- 5.1. Drug Class Market Share, 2024 & 2033
- 5.2. Drug Class Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
- 5.4. Factor Xa Inhibitors
- 5.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 5.5. Thrombin Inhibitors
- 5.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 5.6. Heparins
- 5.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 5.7. P2Y12 Platelet Inhibitors
- 5.7.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 5.8. Others
- 5.8.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Thrombosis Drugs Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Thrombosis Drugs Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
- 7.4. North America
- 7.4.1. North America Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Disease Prevalence
- 7.4.2.3. Regulatory Framework/Reimbursement Framework
- 7.4.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Disease Prevalence
- 7.4.3.3. Regulatory Framework/Reimbursement Framework
- 7.4.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Disease Prevalence
- 7.4.4.3. Regulatory Framework/Reimbursement Framework
- 7.4.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Disease Prevalence
- 7.5.2.3. Regulatory Framework/Reimbursement Framework
- 7.5.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Disease Prevalence
- 7.5.3.3. Regulatory Framework/Reimbursement Framework
- 7.5.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Disease Prevalence
- 7.5.4.3. Regulatory Framework/Reimbursement Framework
- 7.5.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Disease Prevalence
- 7.5.5.3. Regulatory Framework/Reimbursement Framework
- 7.5.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Disease Prevalence
- 7.5.6.3. Regulatory Framework/Reimbursement Framework
- 7.5.6.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Disease Prevalence
- 7.5.7.3. Regulatory Framework/Reimbursement Framework
- 7.5.7.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Disease Prevalence
- 7.5.8.3. Regulatory Framework/Reimbursement Framework
- 7.5.8.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Disease Prevalence
- 7.5.9.3. Regulatory Framework/Reimbursement Framework
- 7.5.9.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Disease Prevalence
- 7.6.2.3. Regulatory Framework/Reimbursement Framework
- 7.6.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Disease Prevalence
- 7.6.3.3. Regulatory Framework/Reimbursement Framework
- 7.6.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Disease Prevalence
- 7.6.4.3. Regulatory Framework/Reimbursement Framework
- 7.6.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Disease Prevalence
- 7.6.5.3. Regulatory Framework/Reimbursement Framework
- 7.6.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Disease Prevalence
- 7.6.6.3. Regulatory Framework/Reimbursement Framework
- 7.6.6.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Disease Prevalence
- 7.6.7.3. Regulatory Framework/Reimbursement Framework
- 7.6.7.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Disease Prevalence
- 7.7.2.3. Regulatory Framework/Reimbursement Framework
- 7.7.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Disease Prevalence
- 7.7.3.3. Regulatory Framework/Reimbursement Framework
- 7.7.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Thrombosis Drugs Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Disease Prevalence
- 7.8.2.3. Regulatory Framework/Reimbursement Framework
- 7.8.2.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Disease Prevalence
- 7.8.3.3. Regulatory Framework/Reimbursement Framework
- 7.8.3.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Disease Prevalence
- 7.8.4.3. Regulatory Framework/Reimbursement Framework
- 7.8.4.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Disease Prevalence
- 7.8.5.3. Regulatory Framework/Reimbursement Framework
- 7.8.5.4. Thrombosis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Bristol-Myers Squibb Company
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Johnson & Johnson
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Boehringer Ingelheim International GmbH
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. SANOFI
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. AstraZeneca
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Pfizer Inc.
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. CSL
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Novo Nordisk A/S
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Takeda Pharmaceutical Company Limited
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Ionis Pharmaceuticals
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.11. Grifols, S.A.
- 8.5.11.1. Overview
- 8.5.11.2. Financial Performance
- 8.5.11.3. Product Benchmarking
- 8.5.11.4. Strategic Initiatives
- 8.5.12. Aspen Holdings
- 8.5.12.1. Overview
- 8.5.12.2. Financial Performance
- 8.5.12.3. Product Benchmarking
- 8.5.12.4. Strategic Initiatives
- 8.5.1. Bristol-Myers Squibb Company
